… type EGFR and patients with EGFR mutations respectively. In either groups of wild-type EGFR
or mutant EGFR, gefitinib and erlotinib did … Erlotinib and gefitinib treatments do not result in …

… To the best of our knowledge, this is the first study worldwide to compare the efficacy of
erlotinib, gefitinib, and afatinib in patients with rare and common EGFR mutations. …

… EGFR mutations with sensitivity to the TKI, gefitinib (17, 18). … inhibitor, erlotinib, contain
similar types of EGFR mutations. … taking gefitinib or erlotinib contain mutations in the EGFR TK …

… Other secondary mutations (D761Y and L747S) are rare. Our goal was to … of erlotinib 150
mg/d in EGFR mutated patients resistant to gefitinib 250 mg/d, because the EGFR TKI erlotinib …

… of uncommon EGFR mutations (13). This question cannot be addressed in this meta-analysis …
gefitinib and erlotinib as most of the included RCTs excluded uncommon EGFR mutations. …

… gefitinib or erlotinib display additional mutations in the EGFR kinase domain, we have examined
the status of EGFR … In all three patients, we found EGFR mutations associated with drug …

… receive erlotinib (150 mg per day) or gefitinib (250 mg per day) orally until disease progression
or unacceptable toxicity. We aimed to determine whether erlotinib is superior to gefitinib …

… If validated, our findings suggest that gefitinib and erlotinib may be effective at delaying
and/or preventing CNS metastases from NSCLC in patients with sensitizing EGFR mutations. As …

… Patient age and EGFR mutation genotype were significant … EGFR mutations initially treated
with gefitinib or erlotinib than … without EGFR mutations and the impact of gefitinib and erlotinib …

… shows the importance of EGFR mutation testing and patient selection according to these test
results for use of erlotinib, as for gefitinib. By comparison with PFS for gefitinib (10.4 months …